Cargando…
AURKA rs2273535 T>A Polymorphism Associated With Cancer Risk: A Systematic Review With Meta-Analysis
Aurora kinase A (AURKA) is a cell cycle regulatory serine/threonine kinase that promotes cell cycle progression. It plays an important role in regulating the transition from G2 to M phase during mitosis. The association between the AURKA rs2273535 T>A polymorphism and cancer risk has been investi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357424/ https://www.ncbi.nlm.nih.gov/pubmed/32733797 http://dx.doi.org/10.3389/fonc.2020.01040 |
_version_ | 1783558683159953408 |
---|---|
author | Wang, Shujie Qi, Jian Zhu, Meiling Wang, Meng Nie, Jinfu |
author_facet | Wang, Shujie Qi, Jian Zhu, Meiling Wang, Meng Nie, Jinfu |
author_sort | Wang, Shujie |
collection | PubMed |
description | Aurora kinase A (AURKA) is a cell cycle regulatory serine/threonine kinase that promotes cell cycle progression. It plays an important role in regulating the transition from G2 to M phase during mitosis. The association between the AURKA rs2273535 T>A polymorphism and cancer risk has been investigated, but the results remain inconsistent. To get a more accurate conclusion, we conducted a comprehensive meta-analysis of 36 case-control studies, involving 22,884 cancer cases and 30,497 healthy controls. Crude odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to determine the association of interest. Pooled analysis indicated that the AURKA rs2273535 T>A polymorphism increased the overall risk of cancer (homozygous: OR = 1.17, 95% CI = 1.04-1.33; recessive: OR = 1.15, 95% CI = 1.05-1.25; allele: OR = 1.07, 95% CI = 1.02-1.13). Stratification analysis by cancer type further showed that this polymorphism was associated with an increased breast cancer risk. This meta-analysis indicated that the AURKA rs2273535 T>A polymorphism was associated with an overall increased cancer risk, especially breast cancer. Further validation experiments are needed to strengthen our conclusion. |
format | Online Article Text |
id | pubmed-7357424 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73574242020-07-29 AURKA rs2273535 T>A Polymorphism Associated With Cancer Risk: A Systematic Review With Meta-Analysis Wang, Shujie Qi, Jian Zhu, Meiling Wang, Meng Nie, Jinfu Front Oncol Oncology Aurora kinase A (AURKA) is a cell cycle regulatory serine/threonine kinase that promotes cell cycle progression. It plays an important role in regulating the transition from G2 to M phase during mitosis. The association between the AURKA rs2273535 T>A polymorphism and cancer risk has been investigated, but the results remain inconsistent. To get a more accurate conclusion, we conducted a comprehensive meta-analysis of 36 case-control studies, involving 22,884 cancer cases and 30,497 healthy controls. Crude odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to determine the association of interest. Pooled analysis indicated that the AURKA rs2273535 T>A polymorphism increased the overall risk of cancer (homozygous: OR = 1.17, 95% CI = 1.04-1.33; recessive: OR = 1.15, 95% CI = 1.05-1.25; allele: OR = 1.07, 95% CI = 1.02-1.13). Stratification analysis by cancer type further showed that this polymorphism was associated with an increased breast cancer risk. This meta-analysis indicated that the AURKA rs2273535 T>A polymorphism was associated with an overall increased cancer risk, especially breast cancer. Further validation experiments are needed to strengthen our conclusion. Frontiers Media S.A. 2020-06-30 /pmc/articles/PMC7357424/ /pubmed/32733797 http://dx.doi.org/10.3389/fonc.2020.01040 Text en Copyright © 2020 Wang, Qi, Zhu, Wang and Nie. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Wang, Shujie Qi, Jian Zhu, Meiling Wang, Meng Nie, Jinfu AURKA rs2273535 T>A Polymorphism Associated With Cancer Risk: A Systematic Review With Meta-Analysis |
title | AURKA rs2273535 T>A Polymorphism Associated With Cancer Risk: A Systematic Review With Meta-Analysis |
title_full | AURKA rs2273535 T>A Polymorphism Associated With Cancer Risk: A Systematic Review With Meta-Analysis |
title_fullStr | AURKA rs2273535 T>A Polymorphism Associated With Cancer Risk: A Systematic Review With Meta-Analysis |
title_full_unstemmed | AURKA rs2273535 T>A Polymorphism Associated With Cancer Risk: A Systematic Review With Meta-Analysis |
title_short | AURKA rs2273535 T>A Polymorphism Associated With Cancer Risk: A Systematic Review With Meta-Analysis |
title_sort | aurka rs2273535 t>a polymorphism associated with cancer risk: a systematic review with meta-analysis |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357424/ https://www.ncbi.nlm.nih.gov/pubmed/32733797 http://dx.doi.org/10.3389/fonc.2020.01040 |
work_keys_str_mv | AT wangshujie aurkars2273535tapolymorphismassociatedwithcancerriskasystematicreviewwithmetaanalysis AT qijian aurkars2273535tapolymorphismassociatedwithcancerriskasystematicreviewwithmetaanalysis AT zhumeiling aurkars2273535tapolymorphismassociatedwithcancerriskasystematicreviewwithmetaanalysis AT wangmeng aurkars2273535tapolymorphismassociatedwithcancerriskasystematicreviewwithmetaanalysis AT niejinfu aurkars2273535tapolymorphismassociatedwithcancerriskasystematicreviewwithmetaanalysis |